PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A01N 37/18, 43/04, C12Q 1/00, 1/02, 1/68, C12N 5/00, 5/06, 15/00, 15/06, 15/09, 15/10, 15/11, G01N 33/53

A2

(11) International Publicati n Number: **WO 98/54963**

(43) International Publication Date: 10 December 1998 (10.12.98)

(21) International Application Number: PCT/US98/11422

(22) International Filing Date: 4 June 1998 (04.06.98)

(30) Priority Data:

60/048,915	6 June 1997 (06.06.97)	US
60/048,882	6 June 1997 (06.06.97)	US

(Continued on the following page)

(71) Applicant *(for all designated States except US)*: HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: YOUNG, Paul [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). GREENE, John, M. [US/US]; 872 Diamond Drive, Gaithersburg, MD 20878 (US). FERRIE, Ann, M. [US/US]; 13203 L Astoria Hill Court, Germantown, MD 20874 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). HU, Jing-Shan [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mt. Nebo Road, Poolesville, MD 20837 (US). MOORE, Paul, A. [GB/US]; Apartment 104, 1908 Holly Ridge Drive, McLean, VA 22102 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). FLORENCE, Charles [US/US]; (US). FLORENCE, Kimberly [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). LAFLEUR, David, W. [US/US]; 1615 Q Street, N.W. #807, Washington, DC 20009 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FAN, Ping [CN/US]; Apartment 302, 335 West Side Drive, Gaithesburg, MD 20878 (US). WEI, Ying-Fei [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). FISCHER, Carrie, L. [US/US]; 5810 Hall Street, Burke, VA 22015 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). LI, Yi [CN/US]; 1247 Lakeside Drive #3034, Sunnyvale, CA 94086 (US). ZENG, Zhizhen [CN/US]; 13950 Saddleview Drive, Gaithersburg, MD 20878 (US). KYAW, Hla [MM/US]; 520 Sugarbush Circle, Frederick, MD 21703 (US). YU, Guo-Liang [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). DILLON, Patrick, J. [US/US]; 1055 Snipe Court, Carlsbad, CA 92009 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). CARTER, Kenneth, C. [US/US]; 11601 Brandy Hall Lane, North Potomac, MD 20878 (US).

(74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 10850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.

(54) Title: 207 HUMAN SECRETED PROTEINS

60/048,892	6 June 1997 (06.06.97)	US
60/048,901	6 June 1997 (06.06.97)	US
60/048,900	6 June 1997 (06.06.97)	US
60/048,893	6 June 1997 (06.06.97)	US
60/048,964	6 June 1997 (06.06.97)	US
60/048,884	6 June 1997 (06.06.97)	US
60/048,894	6 June 1997 (06.06.97)	US
60/048,971	6 June 1997 (06.06.97)	US
60/048,885	6 June 1997 (06.06.97)	US
60/049,375	6 June 1997 (06.06.97)	US
60/048,881	6 June 1997 (06.06.97)	US
60/048,880	6 June 1997 (06.06.97)	US
60/048,896	6 June 1997 (06.06.97)	US
60/049,020	6 June 1997 (06.06.97)	US
60/048,876	6 June 1997 (06.06.97)	US
60/048,895	6 June 1997 (06.06.97)	US
60/049,019	6 June 1997 (06.06.97)	US
60/048,916	6 June 1997 (06.06.97)	US
60/048,970	6 June 1997 (06.06.97)	US
60/048,972	6 June 1997 (06.06.97)	US
60/048,949	6 June 1997 (06.06.97)	US
60/048,974	6 June 1997 (06.06.97)	US
60/048,883	6 June 1997 (06.06.97)	US
60/048,897	6 June 1997 (06.06.97)	US
60/048,898	6 June 1997 (06.06.97)	US
60/049,373	6 June 1997 (06.06.97)	US
60/048,917	6 June 1997 (06.06.97)	US
60/048,962	6 June 1997 (06.06.97)	US
60/048,878	6 June 1997 (06.06.97)	US
60/049,374	6 June 1997 (06.06.97)	US
60/048,875	6 June 1997 (06.06.97)	US
60/048,899	6 June 1997 (06.06.97)	US
60/048,877	6 June 1997 (06.06.97)	US
60/048,963	6 June 1997 (06.06.97)	US
60/057,651	5 September 1997 (05.09.97)	US
60/057,769	5 September 1997 (05.09.97)	US
60/057,643	5 September 1997 (05.09.97)	US
60/057,645	5 September 1997 (05.09.97)	US
60/057,668	5 September 1997 (05.09.97)	US
60/057,635	5 September 1997 (05.09.97)	US
60/057,627	5 September 1997 (05.09.97)	US
60/057,667	5 September 1997 (05.09.97)	US
60/057,666	5 September 1997 (05.09.97)	US
60/057,764	5 September 1997 (05.09.97)	US
60/057,644	5 September 1997 (05.09.97)	US
60/057,765	5 S ptember 1997 (05.09.97)	US
60/057,762	5 September 1997 (05.09.97)	US
60/057,775	5 September 1997 (05.09.97)	US
60/057,634	5 September 1997 (05.09.97)	US
60/057,777	5 September 1997 (05.09.97)	US
60/057,628	5 September 1997 (05.09.97)	US
60/057,776	5 September 1997 (05.09.97)	US
60/057,760	5 September 1997 (05.09.97)	US
60/057,761	5 September 1997 (05.09.97)	US
60/057,771	5 September 1997 (05.09.97)	US
60/057,770	5 September 1997 (05.09.97)	US
60/057,649	5 September 1997 (05.09.97)	US
60/057,774	5 September 1997 (05.09.97)	US
60/057,648	5 September 1997 (05.09.97)	US
60/057,642	5 September 1997 (05.09.97)	US
60/057,629	5 September 1997 (05.09.97)	US
60/057,778	5 September 1997 (05.09.97)	US
60/057,763	5 September 1997 (05.09.97)	US
60/057,584	5 September 1997 (05.09.97)	US
60/057,654	5 September 1997 (05.09.97)	US
60/057,646	5 September 1997 (05.09.97)	US
60/057,662	5 September 1997 (05.09.97)	US
60/057,650	5 September 1997 (05.09.97)	US
60/057,661	5 September 1997 (05.09.97)	US
60/057,647	5 September 1997 (05.09.97)	US
60/070,923	18 December 1997 (18.12.97)	US

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide

AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as

described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a

(2) INFORMATION FOR SEQ ID NO: 425:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 92 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 425:

Met Gly Leu Lys Leu Asn Gly Arg Tyr Ile Ser Leu Ile Leu Ala Val
1 5 10 15

Gln Ile Ala Tyr Leu Val Gln Ala Val Arg Ala Ala Gly Lys Cys Asp
20 25 30

Ala Val Phe Lys Gly Phe Ser Asp Cys Leu Leu Lys Leu Gly Asp Thr
35 40 45

Trp Pro Thr Thr Arg Ser Leu Gly Arg Gln Asp Glu His Gln Asp Arg
50 55 60

Val His Ile Leu Gly Gly Phe Pro Gln Leu His Gly His Ser Pro Tyr
65 70 75 80

Gly Leu Pro Gly Arg Gly Glu Arg Tyr Val Gly Xaa
85 90

(2) INFORMATION FOR SEQ ID NO: 426:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 380 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 426:

Met Ala Arg Arg Ser Ala Phe Pro Ala Ala Ala Leu Trp Leu Trp Ser
1 5 10 15

Ile Leu Leu Cys Leu Leu Ala Leu Arg Ala Glu Ala Gly Pro Pro Gln
20 25 30

Glu Glu Ser Leu Tyr Leu Trp Ile Asp Ala His Gln Ala Arg Val Leu
35 40 45

Ile Gly Phe Glu Glu Asp Ile Leu Ile Val Ser Glu Gly Lys Met Ala
50 55 60

Pro Phe Thr His Asp Phe Arg Lys Ala Gln Gln Arg Met Pro Ala Ile
65 70 75 80

Pro Val Asn Ile His Ser Met Asn Phe Thr Trp Gln Ala Ala Gly Gln
85 90 95

Ala Glu Tyr Phe Tyr Glu Phe Leu Ser Leu Arg Ser Leu Asp Lys Gly
100 105 110

Ile Met Ala Asp Pro Thr Val Asn Val Pro Leu Leu Gly Thr Val Pro
115 120 125

His Lys Ala Ser Val Val Gln Val Gly Phe Pro Cys Leu Gly Lys Gln
130 135 140

Asp Gly Val Ala Ala Phe Glu Val Asp Val Ile Val Met Asn Ser Glu
145 150 155 160

Gly Asn Thr Ile Leu Gln Thr Pro Gln Asn Ala Ile Phe Phe Lys Thr
165 170 175

Cys Gln Gln Ala Glu Cys Pro Gly Gly Cys Arg Asn Gly Gly Phe Cys
180 185 190

Asn Glu Arg Arg Ile Cys Glu Cys Pro Asp Gly Phe His Gly Pro His
195 200 205

Cys Glu Lys Ala Leu Cys Thr Pro Arg Cys Met Asn Gly Gly Leu Cys
210 215 220

Val Thr Pro Gly Phe Cys Ile Cys Pro Pro Gly Phe Tyr Gly Val Asn
225 230 235 240

Cys Asp Lys Ala Asn Cys Ser Thr Thr Cys Phe Asn Gly Gly Thr Cys
245 250 255

Phe Tyr Pro Gly Lys Cys Ile Xaa Pro Pro Gly Leu Glu Gly Glu Gln
260 265 270

Cys Glu Ile Ser Lys Cys Pro Gln Pro Cys Arg Asn Gly Gly Lys Cys
275 280 285

Ile Gly Lys Ser Lys Cys Lys Xaa Ser Lys Gly Tyr Gln Gly Asp Leu
290 295 300

Cys Ser Lys Pro Val Cys Glu Pro Gly Cys Gly Ala His Gly Thr Cys
305 310 315 320

His Glu Pro Asn Lys Cys Gln Cys Gln Glu Gly Trp His Gly Arg His
325 330 335

Cys Asn Lys Arg Tyr Glu Ala Ser Leu Ile His Ala Leu Arg Pro Ala
340 345 350

Gly Ala Gln Leu Arg Gln His Thr Pro Ser Leu Lys Lys Ala Glu Glu
355 360 365

Arg Arg Asp Pro Pro Glu Ser Asn Tyr Ile Trp Xaa
370 375 380

(2) INFORMATION FOR SEQ ID NO: 427:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 427: